These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34930156)

  • 21. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.
    Santra S; Bhattacharya A; Mukhopadhyay T; Agrawal D; Kumar S; Das P; Chakrabarty P
    Mymensingh Med J; 2015 Oct; 24(4):838-44. PubMed ID: 26620028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients.
    Bordbar M; Haghpanah S; Zekavat OR; Saki F; Bazrafshan A; Bozorgi H
    Expert Rev Hematol; 2019 Nov; 12(11):997-1003. PubMed ID: 31486684
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H; Qin Y; Chen G; Zhao Y
    Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J; Wang P; Li X; Wang Q; Zhang J; Lin Y
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020029. PubMed ID: 32395218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.
    Li J; Lin Y; Li X; Zhang J
    Mediterr J Hematol Infect Dis; 2019; 11(1):e2019036. PubMed ID: 31308912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH; Mrkobrada M
    Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
    Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
    Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
    Zardkhoni SZ; Moghaddam AG; Rad F; Ghatee MA; Omidifar N; Ghaedi M; Etemadfar P
    Hemoglobin; 2021 Mar; 45(2):103-106. PubMed ID: 33896336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
    Elalfy MS; Abdin IA; El Safy UR; Ibrahim AS; Ebeid FS; Salem DS
    Hematol Oncol Stem Cell Ther; 2010; 3(4):174-8. PubMed ID: 21150236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
    Lal A; Porter J; Sweeters N; Ng V; Evans P; Neumayr L; Kurio G; Harmatz P; Vichinsky E
    Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
    Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.